AT409218B - Use of taurine for improving psychomotor performance and coordination - Google Patents

Abstract

The use of a composition containing 0.05 to 50 g/l taurine, 0.1 to 10 g/l glucuronolactone, 0.1 to 1 g/l caffeine, 1 to 50 g/l glucose, 10 to 150 g/l sucrose and 20 to 500 mg/l inositol for the non-therapeutic improvement of psychomotor performance and coordination.

Description

AT 409 21 8 B

The invention relates to the use of taurine or taurine-containing compositions.

Taurine (aminoethyl sulfonic acid) is a metabolite of the sulfur-containing amino acid cysteine. A number of medical and non-medical indications have been described for taurine 5, e.g. for the treatment of heart failure, epilepsy, for reducing or reducing the formation of body fat or for lipid peroxidation. Compositions containing taurine are sold under the Red Bull® brand name.

WO 00 62812 A1 relates to a composition for improving cognitive performance, which i.a. Contains taurine. What is meant by " improved cognitive performance " (" Improved Cognitive 10 Performance ") is understood in detail, but is not generally discussed in this document. In the examples and in the description, only the improvement of "attention-deficit hyperactivity" disorders (attention-deficit hyperactivity disorder (ADHD)) is described. The T.O.V.A measurements used primarily in Example 1 are used here.

FR 2 704 391 A describes a composition containing taurine which is said to lead to an improvement in stress adaptation, whereby both physical stress (accident, surgery, etc.) and physiological stress can be considered as stress situations.

U.S. Patent 4,980,168 A also relates to a composition containing L-taurine, which i.a. can be used in hyperactive children.

Finally, US Pat. No. 5,602,150 A relates to the use of taurine for the treatment or prevention of tardive dyskinesia in schizophrenic people in combination with a neuroleptic drug blocking D2 receptor.

The object of the present invention is to provide a new use for taurine or taurine-containing agents.

This object is achieved by the use of a composition containing 0.05 to 25 50 g of taurine / I, 0.1 to 10 g of glucuronolactone / I, 0.1 to 1 g of caffeine / I, 1 to 50 g of glucose / I, 10 to 150 g

Sucrose / I and 20 to 500 mg lnosit / l, for non-therapeutic improvement in psychomotor performance and coordination.

It has surprisingly been found according to the invention that the psychomotor functions of a mammal, including humans, can be selectively and significantly improved by administration of the composition according to the invention, even though the cognitive functions, such as learning and memory, remain unchanged when administration of the composition according to the invention and no anxiety or exploratory behavior is associated with such administration.

According to the invention, these circumstances could be selectively proven by recognized and standardized tests.

According to the invention, the " water maze test " (a test system for cognitive functions such as learning and memory), the " elevated plus maze test " (a test system for fear and exploratory behavior) and the " rota-rod test " (an assay system for psychomotor performance including coordination) (Jones et al., (J. Pharm. Pharmacol. 20 (1968), pp. 302-304) 40 and Hamm et al. (J. Neurotrauma. 11 (1994) , Pp. 187-196)). The " rota-rod test " is a standard test that can be used to test motor skills in their entirety, from peripheral regulation to the influence of the central nervous system.

According to the invention, it was possible to prove that taurine administration gave an unchanged test result in the " water maze test " and in the " elevated plus maze test " revealed during the " rota-rod test " 45 showed significant and statistically relevant improvement in psychomotor performance of coordination. The unchanged result of the two pre-tests is a prerequisite for the evaluation of the " rota-rod-test " system (Hoeger et al., Life Sei. 66 (2000), pages 947-962).

According to the invention, the improvement in psychomotor performance and coordination can be brought about not only in healthy individuals, but also in patients in whom the psychomotor performance and coordination are restricted.

The composition to be used according to the invention is preferably provided in aqueous solution, i.e. a composition in aqueous solution is administered to the individual (human or mammal) in order to obtain the effects according to the invention. 55 In the agent to be administered, taurine can preferably be used in an amount of 0.1 2

AT 409 218 B up to 100 g / day, in particular 1 to 10 g / day, or in a concentration of 0.05 to 50 g / l, in particular 0.5 to 5 g / l, can be made available or applied ,

The composition to be administered according to the invention preferably contains further ingredients, in particular vitamins, further auxiliaries and additives or mixtures of these substances.

The respective concentrations in which these additional substances are made available are preferably 1.2 to 2.4 g / l for glucuronolactone, 0.16 to 0.32 g / l for caffeine, 10 to 25 g / l for glucose , 40 to 100 g / l for sucrose, and 100 to 200 mg / l for inositol.

In particular, niacin, vitamin B6, panthenol, vitamin B2 or vitamin B12 can be provided as vitamins, preferred concentrations in the range from 40 to 80 mg / l niacin, 10 to 20 mg / l vitamin B6, 10 to 20 mg / l panthenol, 3 to 6 mg / l vitamin B2 and 1 to 20 ng vitamin B12.

The invention is explained in more detail with reference to the following example, to which it should of course not be restricted.

Example: 80 white, 4-week-old female OF-1 mice (Himberg, Austria) are treated with Altromin® (a nutrient composition containing 23% protein, 5.5% lipid, 4.4% fibers) for a period of 6 months and 5.7% ashes (see Lubec et al., Life Sciences 58 (25) (1996), 2317-2325; incorporated herein by reference)) and kept appropriately. Of these, 20 had free access to water, 20 to a solution of 4 g / l taurine (Red Bull®), 20 to a 1: 1 mixture of 4 g / l taurine solution (Red Bull®) and water, and 20 to a fermented one Tea drink (Kombucha®). The taurine solution, containing 4 mg / l taurine (Red Bull®), also contained 2.4 g / l glucuronolactone, 0.32 g / l caffeine, 86 g / l sucrose, 21 g / l glucose, 200 mg inositol, 80 mg niacin, 20 mg vitamin B6, 20 mg panthenol, 6 mg vitamin B2 and 0.02 mg vitamin B12.

After 6 months of feeding, the following tests were carried out (according to Hoeger et al., Life Sei. 66 (2000), pp. 947-962): " water maze test " " elevated plus maze test " and " rota rod test "

In the rota-rod test, the mice were subjected to training on the Rota-rod device at a rotation speed of 8 rpm until each animal on the " Rod " could linger. Then the rotation speed was increased from 4 to 40 rpm and the maximum time the animal spent on the rotating rod (" rod ") was measured.

Neurological examinations were carried out according to Irwin (Psychopharmacologia 13 (1968), pages 222-257) and 16 different parameters were tested (body position, spatial movement, negative geotaxis, cliff avoidance, transfer excitation, response to acoustic fright, crossing a narrow path, tail lifting, Pelvic elevation, finger approach, visual orientation, vesticular dripping, strength of hold, lattice behavior and body alignment.

The statistical investigations were carried out using Kruskal Wallis and Mann-Whitney U-Test. A p < 0.05 was considered statistically significant.

It turned out that in the " water maze test " No changes compared to confrontation were found in all groups, i.e. that learning and memory were not changed in any group of mice at this time.

In the " elevated plus maze test " there was also no change in fear and exploratory behavior.

The unchanged result of both tests is a prerequisite for the evaluation of the " rota-rod system ".

The mean residence time of the animals in the rota-rod test was as follows:

Control group (water) 59 s (± 11)

Red Bull®: water (taurine 2 g / l) 71 s (± 9)

Red Bull® (Taurine 4 g / l) 68 s (± 8)

Kombucha group 57 s (+/- 10)

Since the neurological examination did not differ between the individual groups 3

Claims (5)

AT 409 218 B showed, the results from the rota-rod test are directly comparable in terms of the individual groups and it was shown that the psychomotor functions that were brought about peripherally or centrally by the taurine composition were improved significantly and statistically relevant could. PATENT CLAIMS: 1. Use of a composition containing 0.05 to 50 g taurine / l, 0.1 to 10 g glucuronolactone / l, 0.1 to 1 g caffeine / l, 1 to 50 g glucose / l, 10 up to 150 g sucrose / I and 20 to 500 mg inositol / I, for non-therapeutic improvement in psychomotor performance and coordination. 2. Use according to claim 1, characterized in that the composition is made available in aqueous solution. 3. Use according to one of claims 1 or 2, characterized in that the composition is used by taurine in an amount of 0.1 to 100 g per day, in particular 1 to 10 g per day, or in a concentration of 0, 05 to 50 g / l, in particular 0.5 to 5 g / l, is provided. 4. Use according to one of claims 1 to 3, characterized in that further vitamins, further auxiliaries and additives or mixtures of these substances are provided in the composition. 5. Use according to claim 4, characterized in that, independently of one another, glucuronolactone in a concentration of 1.2 to 2.4 g / l, caffeine in a concentration of 0.16 to 0.32 g / l, glucose in one Concentration of 10 to 25 g / l, sucrose in a concentration of 40 to 100 g / l, and inositol in a concentration of 100 to 200 mg / l. NO DRAWING 4